Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cognitive decline, Alzheimer's disease (AD) and other causes are major public health problems worldwide. With changing demographics, the number of persons with dementia will increase rapidly. The treatment and prevention of AD and other dementias, therefore, is an urgent unmet need. There have been considerable advances in understanding the biology of many age-related disorders that cause dementia. Gains in understanding AD have led to the development of ante-mortem biomarkers of traditional neuropathology and the conduct of several phase III interventions in the amyloid-β cascade early in the disease process. Many other intervention strategies are in various stages of development. However, efforts to date have met with limited success. A recent National Institute on Aging Research Summit led to a number of requests for applications. One was to establish multi-disciplinary teams of investigators who use systems biology approaches and stem cell technology to identify a new generation of AD targets. We were recently awarded one of three such grants to build a pipeline that integrates epidemiology, systems biology, and stem cell technology to discover and validate novel therapeutic targets and lead compounds for AD treatment and prevention. Here we describe the two cohorts that provide the data and biospecimens being exploited for our pipeline and describe the available unique datasets. Second, we present evidence in support of a chronic disease model of AD that informs our choice of phenotypes as the target outcome. Third, we provide an overview of our approach. Finally, we present the details of our planned drug discovery pipeline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128
Self-citationRetractedGorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“Pathologic criteria have likewise been revised [13].”
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657
Self-citationDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258
Self-citationAnterior cingulate cortex and conflict detection: an update of theory and data
Carter, C. S., & van Veen, V. (2007) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/cabn.7.4.367 · Cited by 1,056 · cited 1×
“This led us to select the DLPFC which had been implicated in an extraordinarily wide range of these phenotypes [103-119].”
BackgroundInflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
The neuropathology of probable Alzheimer disease and mild cognitive impairment
Schneider, J. A., Arvanitakis, Z., Leurgans, S. E., & Bennett, D. A. (2009) · Annals of Neurology · doi:10.1002/ana.21706 · Cited by 935
Self-citationTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857 · cited 1×
“The new knowledge is being translated into clinical settings via the development of biofluid and neuroimaging biomarkers of the commonly accepted pathologies, which are now being incorporated into clinical trials of disease modifying pharmacotherapies [14-31].”
BackgroundIndividual differences in rates of change in cognitive abilities of older persons.
Wilson, R. S., Beckett, L. A., Barnes, L. L., Schneider, J. A., Bach, J., Evans, D. A., & Bennett, D. A. (2002) · Psychology and Aging · doi:10.1037/0882-7974.17.2.179 · Cited by 842 · cited 1×
“The clinical evaluation has been previously described in detail [66-71].”
MethodSelf-citationThe secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“A number of disease modifying clinical trials have been conducted over the past decade, many focused on amyloid metabolism [34-45].”
BackgroundFull dynamic range proteome analysis of S. cerevisiae by targeted proteomics
Picotti, P., Bodenmiller, B., Mueller, L. N., Domon, B., & Aebersold, R. (2009) · Cell · doi:10.1016/j.cell.2009.05.051 · Cited by 744
Prodromal Alzheimer's disease: successive emergence of the clinical symptoms
Amieva, H., Le Goff, M., Millet, X., Orgogozo, J. M., Pérès, K., Barberger‐Gateau, P., Jacqmin‐Gadda, H., & Dartigues, J. F. (2008) · Annals of Neurology · doi:10.1002/ana.21509 · Cited by 737
Neuropathologic Features of Amnestic Mild Cognitive Impairment
Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., Jicha, G. A., Ivnik, R. J., Smith, G. E., Tangalos, E. G., et al. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.665 · Cited by 616
Neural mechanisms of imitation
Iacoboni, M. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.10.010 · Cited by 606
CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
Initiative, T. A. D. N., Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., Rosenkrantz, L. L., Imboywa, S., Lee, M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3435 · Cited by 570
Self-citationLongitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
Caselli, R. J., Dueck, A. C., Osborne, D., Sabbagh, M. N., Connor, D. J., Ahern, G. L., Baxter, L. C., Rapcsak, S. Z., Shi, J., Woodruff, B. K., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809437 · Cited by 528
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L., & Arnold, S. E. (2004) · Archives of Neurology · doi:10.1001/archneur.61.3.378 · Cited by 526 · cited 1×
“The detailed neuropathologic evaluation has been previously described [72-79].”
MethodSelf-citationUnbiased Reconstruction of a Mammalian Transcriptional Network Mediating Pathogen Responses
Amit, I., Garber, M., Chevrier, N., Leite, A. P., Donner, Y., Eisenhaure, T., Guttman, M., Grenier, J. K., Li, W., Zuk, O., et al. (2009) · Science · doi:10.1126/science.1179050 · Cited by 488
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
Nakashima-Yasuda, H., Uryu, K., Robinson, J., Xie, S. X., Hurtig, H., Duda, J. E., Arnold, S. E., Siderowf, A., Grossman, M., Leverenz, J. B., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0261-2 · Cited by 468
Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women
Bove, R., Secor, E., Chibnik, L. B., Barnes, L. L., Schneider, J. A., Bennett, D. A., & De Jager, P. L. (2014) · Neurology · doi:10.1212/wnl.0000000000000033 · Cited by 437
Self-citationPathological correlates of dementia in a longitudinal, population‐based sample of aging
Sonnen, J. A., Larson, E. B., Crane, P. K., Haneuse, S., Li, G., Schellenberg, G. D., Craft, S., Leverenz, J. B., & Montine, T. J. (2007) · Annals of Neurology · doi:10.1002/ana.21208 · Cited by 432
Probing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Promising Strategies for the Prevention of Dementia
Middleton, L. E., & Yaffe, K. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.201 · Cited by 396 · cited 1×
“Over the past 25 years, the aging and dementia research community has made progress in identifying risk factors for the disease and in characterizing the clinical and pathologic features of the disease [1-9].”
BackgroundCerebral amyloid angiopathy pathology and cognitive domains in older persons
Arvanitakis, Z., Leurgans, S. E., Wang, Z., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2011) · Annals of Neurology · doi:10.1002/ana.22112 · Cited by 383
Self-citationBlumenfeld, R. S., & Ranganath, C. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2353-05.2006 · Cited by 383
Treusch, S., Hamamichi, S., Goodman, J. L., Matlack, K. E. S., Chung, C. Y., Baru, V., Shulman, J. M., Parrado, A., Bevis, B. J., Valastyan, J. S., et al. (2011) · Science · doi:10.1126/science.1213210 · Cited by 379
Self-citationEarly and late life cognitive activity and cognitive systems in old age
WILSON, R. S., BARNES, L. L., KRUEGER, K. R., HOGANSON, G., BIENIAS, J. L., & BENNETT, D. A. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050459 · Cited by 355
Self-citationMuch of late life cognitive decline is not due to common neurodegenerative pathologies
Boyle, P. A., Wilson, R. S., Yu, L., Barr, A. M., Honer, W. G., Schneider, J. A., & Bennett, D. A. (2013) · Annals of Neurology · doi:10.1002/ana.23964 · Cited by 323
Self-citationPreclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · cited 1×
“A number of studies are underway targeting amyloid with this approach [49-51].”
BackgroundCorrelates of susceptibility to scams in older adults without dementia
James, B. D., Boyle, P. A., & Bennett, D. A. (2014) · Journal of Elder Abuse & Neglect · doi:10.1080/08946566.2013.821809 · Cited by 280 · cited 1×
“They include parkinsonism and gait disturbance, motor neuron disease, physical frailty, and a wide variety of other phenotypes that are affected by aging or modify the effect of aging on adverse health outcomes, including sleep and circadian rhythms, pain, menopause, social cognition, experiential factors, depression,…”
BackgroundSelf-citationCognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies
Schneider, J. A., Arvanitakis, Z., Yu, L., Boyle, P. A., Leurgans, S. E., & Bennett, D. A. (2012) · Brain · doi:10.1093/brain/aws234 · Cited by 273
Self-citationA phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258 · cited 1×
“A number of disease modifying clinical trials have been conducted over the past decade, many focused on amyloid metabolism [34-45].”
BackgroundNeurodegenerative basis of age-related cognitive decline
Wilson, R. S., Leurgans, S. E., Boyle, P. A., Schneider, J. A., & Bennett, D. A. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39adc · Cited by 234
Self-citationRelation of neuropathology to cognition in persons without cognitive impairment
Bennett, D. A., Wilson, R. S., Boyle, P. A., Buchman, A. S., & Schneider, J. A. (2012) · Annals of Neurology · doi:10.1002/ana.23654 · Cited by 220 · cited 2×
“The detailed neuropathologic evaluation has been previously described [72-79].”
BackgroundMethodSelf-citationCardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189 · cited 1×
“Over the past 25 years, the aging and dementia research community has made progress in identifying risk factors for the disease and in characterizing the clinical and pathologic features of the disease [1-9].”
BackgroundThe potential of functional MRI as a biomarker in early Alzheimer's disease
Sperling, R. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.009 · Cited by 187 · cited 1×
“The new knowledge is being translated into clinical settings via the development of biofluid and neuroimaging biomarkers of the commonly accepted pathologies, which are now being incorporated into clinical trials of disease modifying pharmacotherapies [14-31].”
BackgroundGenome-wide association study of the rate of cognitive decline in Alzheimer’s disease
Sherva, R., Tripodis, Y., Bennett, D. A., Chibnik, L. B., Crane, P. K., de Jager, P. L., Farrer, L. A., Saykin, A. J., Shulman, J. M., Naj, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.008 · Cited by 180
Self-citationSystematic Discovery of TLR Signaling Components Delineates Viral-Sensing Circuits
Chevrier, N., Mertins, P., Artyomov, M. N., Shalek, A. K., Iannacone, M., Ciaccio, M. F., Gat-Viks, I., Tonti, E., DeGrace, M. M., Clauser, K. R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.10.022 · Cited by 179
CR1 is associated with amyloid plaque burden and age‐related cognitive decline
Chibnik, L. B., Shulman, J. M., Leurgans, S. E., Schneider, J. A., Wilson, R. S., Tran, D., Aubin, C., Buchman, A. S., Heward, C. B., Myers, A. J., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22277 · Cited by 174
Self-citationRaj, T., Ryan, K. J., Replogle, J. M., Chibnik, L. B., Rosenkrantz, L., Tang, A., Rothamel, K., Stranger, B. E., Bennett, D. A., Evans, D. A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt666 · Cited by 144
Neuropathologic Studies of the Baltimore Longitudinal Study of Aging (BLSA)
O'Brien, R. J., Resnick, S. M., Zonderman, A. B., Ferrucci, L., Crain, B. J., Pletnikova, O., Rudow, G., Iacono, D., Riudavets, M. A., Driscoll, I., et al. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1179 · Cited by 137
AD brain pathology: Vascular origins?
Launer, L. J., Petrovitch, H., Ross, G. W., Markesbery, W., & White, L. R. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.008 · Cited by 117
Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people
Bennett, D. A. (2005) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2004.054445 · Cited by 99
Self-citationNeuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles
Bennett, D. A., De Jager, P. L., Leurgans, S. E., & Schneider, J. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a2e87d · Cited by 93
Self-citationDorsolateral Prefrontal Cortex, Working Memory, and Prospective Coding for Action
Mars, R. B., & Grol, M. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5344-06.2007 · Cited by 73
Disentangling the effects of age and APOE on neuropathology and late life cognitive decline
Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.074 · Cited by 71
Self-citationLongitudinal modeling of cognitive aging and the TOMM40 effect
Caselli, R. J., Dueck, A. C., Huentelman, M. J., Lutz, M. W., Saunders, A. M., Reiman, E. M., & Roses, A. D. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.11.006 · Cited by 69
The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Au, R., Seshadri, S., Knox, K., Beiser, A., J. Himali, J., J. Cabral, H., Auerbach, S., C. Green, R., A. Wolf, P., & C. McKee, A. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322609 · Cited by 65
Emotional neglect in childhood and cerebral infarction in older age
Wilson, R. S., Boyle, P. A., Levine, S. R., Yu, L., Anagnos, S. E., Buchman, A. S., Schneider, J. A., & Bennett, D. A. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e25bd · Cited by 63
Self-citationThe neural correlate of consciousness
Bodovitz, S. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.019 · Cited by 24
Correction: Ushering in the study and treatment of preclinical Alzheimer disease
J. B., L. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.145 · Cited by 15
Cited by
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Religious Orders Study and Rush Memory and Aging Project
Bennett, D. A., Buchman, A. S., Boyle, P. A., Barnes, L. L., Wilson, R. S., & Schneider, J. A. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179939 · Cited by 1,260
“The multilayer omics data are now being used to support a novel drug and biomarker discovery pipeline as part of the Accelerating Medicines Partnership-AD (Fig 3) [276, 277].”
Self-citationLugli, G., Cohen, A. M., Bennett, D. A., Shah, R. C., Fields, C. J., Hernandez, A. G., & Smalheiser, N. R. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139233 · Cited by 391
Self-citationGuzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
“Over the years, extensive scientific research has focused on potential disease-modifying therapies for AD [17-19].”
BackgroundGenetic architecture of subcortical brain structures in 38,851 individuals
Satizabal, C. L., Adams, H. H. H., Hibar, D. P., White, C. C., Knol, M. J., Stein, J. L., Scholz, M., Sargurupremraj, M., Jahanshad, N., Roshchupkin, G. V., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0511-y · Cited by 260
Self-citation
Metadata
- Authors
- Bennett, D. A., Yu, L., & De Jager, P. L.
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 88
- Issue
- 4
- Pages
- 617-630
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W2089216251
- Cited by
- 57
- References
- 58
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.